Download PDF
Pharmacopsychiatry 2014; 47(03): 115-117
DOI: 10.1055/s-0034-1371868
Letter
© Georg Thieme Verlag KG Stuttgart · New York

Ibuprofen Dependence: A Case Report

F. Etcheverrigaray   *
1   Center for Evaluation and Information on Pharmacodependence, Clinical Pharmacology Department, University Hospital, Nantes, France
,
M. Grall-Bronnec   *
2   Addictology and Psychiatry Department, University Hospital, Nantes, France
3   EA 4275, Biostatistics, Pharmacoepidemiology and Subjective Measures in Health Sciences, Nantes University, Nantes, France
,
M.-C. Blanchet
2   Addictology and Psychiatry Department, University Hospital, Nantes, France
,
P. Jolliet
1   Center for Evaluation and Information on Pharmacodependence, Clinical Pharmacology Department, University Hospital, Nantes, France
3   EA 4275, Biostatistics, Pharmacoepidemiology and Subjective Measures in Health Sciences, Nantes University, Nantes, France
,
C. Victorri-Vigneau
1   Center for Evaluation and Information on Pharmacodependence, Clinical Pharmacology Department, University Hospital, Nantes, France
3   EA 4275, Biostatistics, Pharmacoepidemiology and Subjective Measures in Health Sciences, Nantes University, Nantes, France
› Author Affiliations
Further Information

Publication History

Publication Date:
24 April 2014 (online)

Also available at
    Permissions and Reprints

Abstract

Ibuprofen is currently widely prescribed and has not been reported to produce dependence. We report the case of a 17-year old patient who presented many positive psychics symptoms related to a pharmacological dependence. During the treatment, she adjusted herself posology as she developed withdrawal symptoms. Pharmacological evidences (effect on COX-1 and COX-2, FAAH and PPARs) allow us to formulate hypotheses explaining this effect.

Key words

ibuprofen - dependence - cannabinoid receptor modulators - peroxisome proliferator-activated

* These two authors are first co-authors.


 

  • References

  • 1 American Psychiatric Association . Diagnostic and statistical manual of mental disorders DSM-IV-TR. Washington, DC: American Psychiatric Publishing; 2000
    Google Scholar
  • 2 American Psychiatric Association . Diagnostic and statistical manual of mental disorders DSM-5. Washington, DC: American Psychiatric Publishing; 2013
    CrossrefGoogle Scholar
  • 3 Zwart J-A, Dyb G, Hagen K et al. Analgesic overuse among subjects with headache, neck, and low-back pain. Neurology 2004; 62: 1540-1544
    CrossrefPubMedGoogle Scholar
  • 4 Abrams BM. Medication overuse headaches. Med Clin North Am 2013; 97: 337-352
    CrossrefPubMedGoogle Scholar
  • 5 Elkind AH. Drug abuse and headache. Med Clin North Am 1991; 75: 717-732
    PubMedGoogle Scholar
  • 6 Beaulieu P, Lambert C. Précis de pharmacologie. Du fondamental à la clinique. Les Presses de l’Université de Montréal 2010
    PubMedGoogle Scholar
  • 7 Ito S, Okuda-Ashitaka E, Minami T. Central and peripheral roles of prostaglandins in pain and their interactions with novel neuropeptides nociceptin and nocistatin. Neurosci Res 2001; 41: 299-332
    CrossrefPubMedGoogle Scholar
  • 8 Wu KK-Y. Biochemical pharmacology of nonsteroidal anti-inflammatory drugs. Biochem Pharmacol 1998; 55: 543-547
    CrossrefPubMedGoogle Scholar
  • 9 Nechifor M, Chelãrescu D, Teslariu E et al. Effects of PGF2alpha analogues in experimental morphine-induced pharmacodependence. Adv Exp Med Biol 2003; 525: 121-124
    PubMedGoogle Scholar
  • 10 Nakagawa T, Minami M, Katsumata S et al. Suppression of naloxone-precipitated withdrawal jumps in morphine-dependent mice by stimulation of prostaglandin EP3 receptor. Br J Pharmacol 1995; 116: 2661-2666
    CrossrefPubMedGoogle Scholar
  • 11 Dajani EZ, Shahwan TG, Dajani NE. Prostaglandins and brain-gut axis. J Physiol Pharmacol Off J Pol Physiol Soc 2003; 54 (Suppl. 04) 155-164
    PubMedGoogle Scholar
  • 12 Paunescu H, Coman OA, Coman L et al. Cannabinoid system and cyclooxygenases inhibitors. J Med Life 2011; 4: 11
    PubMedGoogle Scholar
  • 13 De Petrocellis L, Melck D, Ueda N et al. Brain and peripheral anandamide amidohydrolase and its inhibition by synthetic arachidonate analogues. Adv Exp Med Biol 1997; 433: 259-263
    PubMedGoogle Scholar
  • 14 Pertwee RG. Pharmacological actions of cannabinoids. Handb Exp Pharmacol 2005; 1-51
    PubMedGoogle Scholar
  • 15 Solinas M, Tanda G, Justinova Z et al. The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. J Pharmacol Exp Ther 2007; 321: 370-380
    CrossrefPubMedGoogle Scholar
  • 16 Ramesh D, Gamage TF, Vanuytsel T et al. Dual inhibition of endocannabinoid catabolic enzymes produces enhanced antiwithdrawal effects in morphine-dependent mice. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 2013; 38: 1039-1049
    CrossrefPubMedGoogle Scholar
  • 17 Solinas M, Justinova Z, Goldberg SR et al. Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats. J Neurochem 2006; 98: 408-419
    CrossrefPubMedGoogle Scholar
  • 18 Gamaleddin I, Wertheim C, Zhu AZX et al. Cannabinoid receptor stimulation increases motivation for nicotine and nicotine seeking. Addict Biol 2012; 17: 47-61
    CrossrefPubMedGoogle Scholar
  • 19 Romero TRL, Resende LC, Guzzo LS et al. CB1 and CB2 cannabinoid receptor agonists induce peripheral antinociception by activation of the endogenous noradrenergic system. Anesth Analg 2013; 116: 463-472
    CrossrefPubMedGoogle Scholar
  • 20 Moreira FA, Lutz B. The endocannabinoid system: emotion, learning and addiction. Addict Biol 2008; 13: 196-212
    CrossrefPubMedGoogle Scholar
  • 21 Sim-Selley LJ. Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol 2003; 15: 91-119
    CrossrefPubMedGoogle Scholar
  • 22 Lenhard JM. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997; 272: 3406-3410
    CrossrefPubMedGoogle Scholar
  • 23 Jaradat MS, Wongsud B, Phornchirasilp S et al. Activation of peroxisome proliferator-activated receptor isoforms and inhibition of prostaglandin H(2) synthases by ibuprofen, naproxen, and indomethacin. Biochem Pharmacol 2001; 62: 1587-1595
    CrossrefPubMedGoogle Scholar
  • 24 Pontieri FE, Tanda G, Di Chiara G. Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the “shell” as compared with the “core” of the rat nucleus accumbens. Proc Natl Acad Sci USA 1995; 92: 12304-12308
    CrossrefPubMedGoogle Scholar
  • 25 Schlicht I. Enhancement of voluntary alcohol consumption in rats by clofibrate feeding. Alcohol Fayettev N 1987; 4: 199-206
    PubMedGoogle Scholar
  • 26 Barson JR, Karatayev O, Chang G-Q et al. Positive relationship between dietary fat, ethanol intake, triglycerides, and hypothalamic peptides: counteraction by lipid-lowering drugs. Alcohol Fayettev N 2009; 43: 433-441
    PubMedGoogle Scholar
  • 27 Fernandez-Espejo E, Ramiro-Fuentes S, Rodriguez de Fonseca F. The absence of a functional peroxisome proliferator-activated receptor-alpha gene in mice enhances motor sensitizing effects of morphine, but not cocaine. Neuroscience 2009; 164: 667-675
    CrossrefPubMedGoogle Scholar
  • 28 Panlilio LV, Justinova Z, Mascia P et al. Novel use of a lipid-lowering fibrate medication to prevent nicotine reward and relapse: preclinical findings. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 2012; 37: 1838-1847
    CrossrefPubMedGoogle Scholar
  • 29 Stopponi S, Somaini L, Cippitelli A et al. Activation of nuclear PPARγ receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking. Biol Psychiatry 2011; 6: 642-649
    PubMedGoogle Scholar
  • 30 Maeda T, Kiguchi N, Fukazawa Y et al. Peroxisome proliferator-activated receptor gamma activation relieves expression of behavioral sensitization to methamphetamine in mice. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 2007; 32: 1133-1140
    CrossrefPubMedGoogle Scholar
  • 31 Mascia P, Pistis M, Justinova Z et al. Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors. Biol Psychiatry 2011; 69: 633-641
    CrossrefPubMedGoogle Scholar
  • 32 Sarruf DA, Yu F, Nguyen HT et al. Expression of peroxisome proliferator-activated receptor-gamma in key neuronal subsets regulating glucose metabolism and energy homeostasis. Endocrinology 2009; 150: 707-712
    CrossrefPubMedGoogle Scholar